Clinical experience with the second-generation 3f Enable sutureless aortic valve prosthesis.

Area of Science:

• Cardiovascular Surgery
• Biomaterials Science
• Medical Devices

Background:

• The 3f Enable aortic bioprosthesis is a novel, self-expanding, equine pericardial valve designed for sutureless aortic valve replacement.
• Sutureless implantation aims to reduce procedure time and improve patient outcomes in aortic stenosis treatment.

Purpose of the Study:

• To evaluate the technical aspects, safety, and short-term effectiveness of the 3f Enable aortic bioprosthesis.
• To assess early hemodynamic performance and procedural outcomes in patients undergoing aortic valve replacement.

Main Methods:

• An outcome analysis of 28 consecutive patients with aortic stenosis receiving the 3f Enable valve.
• Data collected included patient demographics, EuroSCORE, operative times, hospital stay, and early postoperative complications.

Main Results:

• Mean aortic crossclamp and cardiopulmonary bypass times were 39 and 58 minutes, respectively.
• 30-day mortality was 3.5%, and 1-year survival was 86.2%.
• Favorable early hemodynamics with low transvalvular gradients were observed; 18.5% required permanent pacemakers.

Conclusions:

• The 3f Enable aortic bioprosthesis can be safely implanted with good early hemodynamic results.
• Sutureless implantation with a self-expanding stent facilitates a large valve area, though procedure times require optimization.
• The study highlights the need for continued design and procedural enhancements for this aortic bioprosthesis.